Potent VEGFR inhibitor (IC50 = 0.035 nM); also inhibits c-Met, KIT, RET, FLT4, AXL, FLT3, FLT1 and Tie2 (IC50 values are 1.3, 4.6, 5.2, 6, 7, 11.3, 12 and 14.3 nM, respectively). Induces intratumoral hypoxia and apoptosis. Reduces tumor invasion and metastasis in vivo. Antiangiogenic.
XL 184 is also offered as part of the Tocriscreen Plus, Tocriscreen Kinase Inhibitor Toolbox II and Tocriscreen Library of FDA-Approved Compounds. Find out more about compound libraries available from Tocris.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 501.51. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.99 mL||9.97 mL||19.94 mL|
|5 mM||0.4 mL||1.99 mL||3.99 mL|
|10 mM||0.2 mL||1 mL||1.99 mL|
|50 mM||0.04 mL||0.2 mL||0.4 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
You et al (2012) VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 71 4758 PMID: 21613405
Yakes et al (2011) Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol.Cancer Ther. 10 2298 PMID: 21926191
If you know of a relevant reference for XL 184, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: XL 184, supplier, Potent, VEGFR, inhibitors, inhibits, HGFR, HGF, receptor, vascular, endothelial, growth, factors, receptor,, tyrosine, kinases, RTKs, c-Met, KIT, FLT4, AXL, FLT3, FLT1, Tie2, apoptosis, metastasis, antiangiogenics, angiogenesis, antitumor, antitumour, Cabozantinib, BMS, 907351, VEGFR, Tocris Bioscience
Citations for XL 184
Citations are publications that use Tocris products.
Currently there are no citations for XL 184. Do you know of a great paper that uses XL 184 from Tocris? If so please let us know.